| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 6359 | 2019 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2799 | 2019 |
| Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal … TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031, 2019 | 754 | 2019 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 727 | 2019 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 655 | 2019 |
| Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 trial ET Kato, RP Giugliano, CT Ruff, Y Koretsune, T Yamashita, RG Kiss, ... Journal of the American Heart Association 5 (5), e003432, 2016 | 322 | 2016 |
| The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... American heart journal 200, 83-89, 2018 | 194 | 2018 |
| DECLARE‐TIMI 58: participants’ baseline characteristics I Raz, O Mosenzon, MP Bonaca, A Cahn, ET Kato, MG Silverman, ... Diabetes, Obesity and Metabolism 20 (5), 1102-1110, 2018 | 158 | 2018 |
| Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) ET Kato, CP Cannon, MA Blazing, E Bohula, S Guneri, JA White, ... Journal of the American Heart Association 6 (11), e006901, 2017 | 73 | 2017 |
| Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation ET Kato, S Goto, RP Giugliano Ageing research reviews 49, 115-124, 2019 | 58 | 2019 |
| The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2-TIMI 51 trial MA Cavender, CM Gibson, E Braunwald, SD Wiviott, SA Murphy, ... European Heart Journal: Acute Cardiovascular Care 4 (5), 468-474, 2015 | 42 | 2015 |
| Infl ammatory mediators in chronic heart failure in North India J Fedacko, RB Singh, A Gupta, K Hristova, E Toda, A Kumar, M Saxena, ... Acta Cardiologica 69 (4), 391-398, 2014 | 42 | 2014 |
| Essential and non-essential amino acids in relation to glutamate T Takahashi, E Toda, RB Singh, F De Meester, A Wilczynska, D Wilson, ... The Open Nutraceuticals Journal 4 (1), 205-212, 2011 | 42 | 2011 |
| Nutrition in transition from Homo sapiens to Homo economicus RB Singh, T Takahashi, T Nakaoka, K Otsuka, E Toda, HH Shin, MK Lee, ... The Open Nutraceuticals Journal 6 (1), 2013 | 41 | 2013 |
| Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions N Tamura, I Kitajima, Y Kawamura, E Toda, Y Eguchi, H Ishida, S Goto Circulation Journal 73 (3), 540-548, 2009 | 34 | 2009 |
| Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48 E Toda Kato, RP Giugliano, CT Ruff, SA Murphy, F Nordio, T Kimura, J Jin, ... Circulation 130 (suppl_2), A16612-A16612, 2014 | 25 | 2014 |
| Intravascular ultrasound-guided percutaneous coronary interventions with minimum contrast volume for prevention of the radiocontrast-induced nephropathy: report of two cases N Ogata, T Matsukage, E Toda, S Tamiya, T Fujii, G Nakazawa, N Masuda, ... Cardiovascular intervention and therapeutics 26, 83-88, 2011 | 19 | 2011 |
| Angiographic evaluation of right upper-limb arterial anomalies: implications for transradial coronary interventions. T Fujii, N Masuda, S Tamiya, M Shima, E Toda, D Ito, G Nakazawa, ... The Journal of invasive cardiology 22 (11), 536-540, 2010 | 14 | 2010 |
| DECLARE-TIMI 58: design and baseline characteristics I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, MG Silverman, ... Diabetes 66, A333-A333, 2017 | 6 | 2017 |
